Povorcitinib (INCB054707), a selective JAK1 inhibitor, is also in early-phase clinical development for IBD, having shown immunomodulatory potential in other inflammatory diseases such as hidradenitis suppurativa [93]. The gene discussed is JAK1; the disease is inflammatory bowel disease.